MDEL Suspension, Cancellation and Reinstatement Requirements

1. Key takeaways

There are two paths by which an MDEL can lapse: failure to meet maintenance obligations (missing the ALR deadline or failing to notify changes on time) and action taken by Health Canada on its own initiative (suspension or cancellation). Reinstating an MDEL requires payment of a fee (CAD 5,519, as of 2026-04-01). The Health Canada MDEL list displays only valid MDELs.

• Lapse can occur through missed maintenance obligations or through suspension or cancellation decided by Health Canada.
• Paragraph 46.1(1), as amended, frames the annual review as a duty of holders whose licence is not suspended, so suspended holders follow the reinstatement path instead.
• The same fee of CAD 5,519 covers a first MDEL, a subsequent annual licence and reinstatement.
• Fees apply equally to foreign and domestic establishments, with no foreign discount.
• Because the public MDEL list shows only valid licences, visibility on that list is itself a compliance signal that partners check.

2. Legal basis

The framework for lapse and reinstatement of an establishment licence is spread across the Regulations, the amended review provision and the fee publications. The table below collects the instruments, provisions, dates and sources that matter for this topic.

The combined effect is that maintenance, lapse and reinstatement are governed by a single coherent framework: the same sections that create the obligations also define what happens when they are not met, and the same fee schedule prices both the ordinary annual licence and the extraordinary case of getting a licence back.

3. Expert insights

Insight 1: paragraph 46.1(1) writes non-suspension into the ALR as a precondition.

The amended paragraph 46.1(1) reads: “The holder of an establishment licence that is not suspended must submit an application for the review of their licence…” This means a suspended holder does not use the annual review process at all; that holder moves onto the reinstatement process instead. The drafting deliberately separates the routine annual track from the exceptional track, and companies should map their internal escalation so that a suspension notice immediately switches the workstream from review preparation to reinstatement preparation rather than leaving the file on the annual calendar.

Insight 2: reinstatement is the fee scenario most often left out of budgets.

The Health Canada fees page states expressly that fees are charged for a first MDEL, a subsequent annual licence and MDEL reinstatement, and all three are set at CAD 5,519 (as of 2026-04-01). Companies typically budget for the first two and overlook the reinstatement scenario. Because a lapse in maintenance obligations can trigger the need to reinstate, the third scenario is not hypothetical risk; it is the direct financial consequence of missing the deadlines covered in the previous article, and it belongs in any serious multi-year budget as a scenario line.

Insight 3: visibility on the MDEL list is itself a compliance signal.

The Health Canada MDEL list displays only valid MDELs. Partners verify cooperation by checking that list directly: once a company is not on the list, both commercial trust and customs-related verification are affected immediately. Distributors, hospitals and procurement teams do not distinguish between a licence that has lapsed by accident and one that was cancelled for cause; from the outside the absence is the same. Continuous self-checking of list visibility therefore protects not only regulatory standing but also the commercial relationships that depend on it, and it costs almost nothing compared with the work required to rebuild those relationships after an unexpected lapse is discovered at the worst possible moment, namely during partner due diligence or a shipment.

Insight 4: foreign and domestic establishments pay the same fee, with no foreign discount.

The Health Canada fees page states that these fees “are applied equally to foreign and domestic establishments”. This is a point of difference in fee design between Canada and the United States (the annual establishment registration fee under MDUFA in the US likewise has no small-business reduction, but the two rate structures differ). Foreign establishments should build their budgets on the identical rate rather than assuming any location-based adjustment will be available.

4. Practical recommendations

• Treat visibility on the MDEL list as a standing monitoring indicator and self-check it on a regular schedule.
• Budget for all three fee scenarios (first licence, annual licence, reinstatement), each at CAD 5,519.
• Establish a contingency plan under which a suspension immediately triggers the reinstatement process, with a named owner and timelines.
• Review whether the paragraph 44(4) exemption still holds if your own licence has lapsed, since the exemption depends on the importer holding a valid MDEL.
• Foreign establishments should budget at the same rate as domestic ones, without expecting a rate difference based on location.

5. Verification checklist

• □ Visibility on the MDEL list is self-checked on a regular schedule
• □ The budget covers the first, annual and reinstatement scenarios (each at CAD 5,519)
• □ A contingency plan is in place under which suspension triggers the reinstatement process
• □ Whether the paragraph 44(4) exemption still holds has been reviewed
• □ Foreign establishments have budgeted at the same rate as domestic establishments
• □ The maintenance obligations of the ALR and change notification are in place

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com